Kin Seng Liem

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Kin Seng Liem, Scott Fung, David Wong et al. · Gut · 2019 · 143 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

Kin Seng Liem, Margo J. H. van Campenhout, Qing Xie et al. · Alimentary Pharmacology & Therapeutics · 2019 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B

Kin Seng Liem, Adam J. Gehring, Jordan J. Feld et al. · Gastroenterology · 2019 · 26 citations · Full text

Pharmacy, Pharmacotherapy, Hepatic Pharmacotherapy +12

Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study.

Cristina Saura, Miguel Martín, R Moroose et al. · Cancer Research · 2009 · 19 citations

Medicine, Oncology, Pharmacology +15

Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B

Kin Seng Liem, Colina Yim, Thomas D. Ying et al. · Liver International · 2019 · 16 citations · Full text

Pharmacy, Community Health, Health Services Research +11